Answers are grounded in this paper and cite their sources.
Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.
No takes yet. Share an insight, caveat, or question.
Schepisi et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: